What is Real Endpoints?
Real Endpoints specializes in facilitating market access for medical innovations, addressing critical issues that hinder the delivery of new therapies to patients. Through a combination of strategic consulting and AI-driven solutions, the company offers comprehensive services including pricing and contracting strategies, patient support programs, payer marketing, and advisory market research specifically designed for biopharma clients.
With a core mission to enhance patient access, Real Endpoints provides platforms such as RE Assist, which offers real-time financial information to support Medicare patients. Their recognized expertise lies in navigating the intricate landscape of market access, with a particular emphasis on rare and orphan therapies, ensuring that life-changing treatments reach those who need them.
How much funding has Real Endpoints raised?
Real Endpoints has raised a total of $363K across 2 funding rounds:
Debt
$150K
Debt
$213K
Debt (2020): $150K with participation from PPP
Debt (2021): $213K led by PPP
What's next for Real Endpoints?
The substantial backing and strategic investment position Real Endpoints for accelerated growth and expanded market penetration. As a company operating in the large-scale, late-stage funding environment, Real Endpoints is poised to scale its operations, enhance its AI-driven solutions, and broaden its service offerings to a wider range of biopharma clients.
Future strategic initiatives are likely to focus on solidifying its market leadership in patient access solutions, potentially through further technological advancements, strategic partnerships, or geographic expansion. The company's ability to secure significant capital indicates strong investor confidence in its business model and its potential to address unmet needs within the healthcare ecosystem.
